Results 21 to 30 of about 179,384 (308)

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

New England Journal of Medicine, 2022
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less.
S. Solomon, J. McMurray, B. Claggett, R. D. de Boer, D. DeMets, Adrian F. Hernandez, S. Inzucchi, M. Kosiborod, C. Lam, F. Martinez, Sanjiv J. Shah, Akshay S. Desai, P. Jhund, J. Bělohlávek, C. Chiang, C. Borleffs, J. Comín-Colet, D. Dobreanu, J. Drożdż, J. Fang, M. Alcocer-Gamba, Waleed Al habeeb, Yaling Han, Jose Walter Cabrera Honorio, S. Janssens, T. Katova, M. Kitakaze, B. Merkely, E. O’Meara, J. Saraiva, S. Tereshchenko, J. Thierer, M. Vaduganathan, O. Vardeny, S. Verma, V. Pham, U. Wilderäng, Natalia Zaozerska, E. Bachus, D. Lindholm, Magnus Petersson, A. Langkilde   +41 more
semanticscholar   +3 more sources

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

New England Journal of Medicine, 2019
BACKGROUND The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction.
S. Solomon, J. McMurray, I. Anand, J. Ge, C. Lam, A. Maggioni, F. Martinez, M. Packer, M. Pfeffer, B. Pieske, M. Redfield, J. Rouleau, D. V. van Veldhuisen, F. Zannad, M. Zile, Akshay S. Desai, Brian Claggett, P. Jhund, S. Boytsov, J. Comín-Colet, J. Cleland, H. Düngen, E. Goncalvesova, T. Katova, J. K. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, Sanjiv J. Shah, Jingmin Zhou, A. Rizkala, J. Gong, V. Shi, M. Lefkowitz   +33 more
semanticscholar   +3 more sources

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. [PDF]

New England Journal of Medicine, 2015
BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients.
Anstrom, Kevin J., Borlaug, Barry A., Braunwald, Eugene, Chen, Horng H., Cole, Robert T., Felker, G. Michael, Joseph, Susan M., Koepp, Gabe A., Levine, James A., LeWinter, Martin M., McNulty, Steven E., Redfield, Margaret M., Reeves, Gordon R., Semigran, Marc J., Shah, Monica R, Shah, Sanjiv J., Tang, W.H. Wilson, Tedford, Ryan J., Velazquez, Eric J.   +18 more
core   +4 more sources

Heart failure with preserved ejection fraction.

Current Emergency and Hospital Medicine Reports, 2019
BACKGROUND Approximately one half of all patients with heart failure have normal ejection fraction in the left ventricle, and heart failure is attributed to stiffness of the cardiac muscle.
O. Smiseth, S. Kjeldsen, Ø. Andersen, Nisha Mistry, A. Westheim, H. Skulstad, E. Gude   +6 more
semanticscholar   +4 more sources

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

Lancet, The
BACKGROUND In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with ...
Javed Butler, Sanjiv J. Shah, Mark C. Petrie, B. Borlaug, S. Z. Abildstrom, M. Davies, G. Hovingh, D. Kitzman, D. V. Møller, Subodh Verma, M. N. Einfeldt, Marie L Lindegaard, S. Rasmussen, W. Abhayaratna, Fozia Z. Ahmed, Tuvia Ben‐Gal, V. Chopra, Justin A. Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, V. Melenovský, Béla Merkely, Julio Núñez, E. Perna, Morten Schou, M. Senni, Kavita Sharma, Peter van der Meer, Dirk von Lewinski, Dennis Wolf, M. Kosiborod   +31 more
semanticscholar   +3 more sources

Heart failure with preserved ejection fraction

Radiopaedia.org, 2021
Calum A. Worsley, J. Feger
semanticscholar   +3 more sources

Biomarker profiles of acute heart failure patients with a mid-range ejection fraction [PDF]

, 2017
OBJECTIVES: In this study, the authors used biomarker profiles to characterize differences between patients with acute heart failure with a midrange ejection fraction (HFmrEF) and compare them with patients with a reduced (heart failure with a ...
Bloomfield, Daniel M, Cleland, John G.F., Cotter, Gad, Davison, Beth, Dittrich, Howard C, Givertz, Michael M, Hillege, Hans L, Khan, Mohsin A F, Mentz, Robert J, Metra, Marco, O'Connor, Christopher M, Ponikowski, Piotr, Teerlink, John R, Tromp, Jasper, van der Meer, Peter, Van Veldhuisen, Dirk J, Voors, Adriaan A.   +16 more
core   +18 more sources

Trends in prevalence and outcome of heart failure with preserved ejection fraction.

New England Journal of Medicine, 2006
Theophilus E. Owan, D. Hodge, R. Herges, S. Jacobsen, V. Roger, M. Redfield   +5 more
semanticscholar   +3 more sources

Outcome of heart failure with preserved ejection fraction in a population-based study.

New England Journal of Medicine, 2006
R. Bhatia, Jack V. Tu, Jack V. Tu, Douglas S. Lee, P. Austin, Jiming Fang, A. Haouzi, Y. Gong, Peter P. Liu, Peter P. Liu   +9 more
semanticscholar   +3 more sources

Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement.

Journal of the American College of Cardiology, 2023
B. Borlaug, K. Sharma, Sanjiv J. Shah, J. Ho   +3 more
semanticscholar   +2 more sources